Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Q2 Bayer Results: Strong Crop‑Protectants, Rising Margins and a Cleaned‑Up Roundup Settlement

Explore Bayer AG’s Q2 results: steady revenue growth, legal win on Roundup, and breakthrough auxin‑based herbicides & oncology drugs. A balanced outlook for investors.

Dr. Michael Chen

15/08/2026, 23:51

4 minutes to read

Johnson & Johnson Stock: Market Pullback vs. Robust Pipeline Growth

Johnson & Johnson’s stock dipped amid a market pullback, but its robust pipeline—from CAR‑T to gene therapy and mRNA vaccines—signals long‑term growth and investor resilience.

Dr. Michael Chen

15/08/2026, 21:30

4 minutes to read

Merck KGaA Expands Oncology Reach: AI‑Driven Remepy Partnership & Bio‑Techne Acquisition Boost Therapeutic Innovation

Merck KGaA strengthens oncology research by partnering with AI‑driven Remepy and acquiring Bio‑Techne’s diagnostics, boosting personalized treatment and lab capabilities.

Dr. Michael Chen

13/08/2026, 23:30

5 minutes to read

Novo Nordisk Shares Rise After Berenberg Downgrade Amid Weight‑Loss Competition

Novo Nordisk’s shares edge up despite a Berenberg downgrade, underscoring investor confidence in its GLP‑1 pipeline, tirzepatide prospects, and resilient diabetes revenue.

Dr. Michael Chen

13/08/2026, 22:19

4 minutes to read

Zoetis Revamps Leadership, Cuts 2026 Forecast, but Launches Promise‑Bearing Feline Pain Drug Portela

Zoetis reshapes leadership & cuts 2026 guidance amid weak US pet‑care demand, but backs up with UK‑approved pain therapy Portela and VitalRADS diagnostics for rapid disease testing.

Dr. Michael Chen

09/08/2026, 21:19

5 minutes to read

Insmed’s BRINSUPRI Breakthrough: Strong Phase III Results, Accelerated FDA Approval, & $14 B Market Potential

Insmed’s BRINSUPRI breakthrough: 30%+ 6‑minute walk improvement, FDA accelerated approval, $7B peak sales, and robust insider confidence—all driving PAH market growth.

Dr. Michael Chen

09/08/2026, 16:08

4 minutes to read

El Ili Lilly Q2 2024: Record GLP‑1 Growth, Mounjaro & Zepbound Surge Ahead

Discover how Eli Lilly’s Q2 2024 results and GLP‑1 drugs Mounjaro & Zepbound drive record sales, superior weight loss, and a bullish market outlook.

Dr. Michael Chen

07/08/2026, 17:27

4 minutes to read

Gilead Q2 2026: $7.8B Revenue Growth, HIV Wins, Yet Acquisition‑Driven Loss

Gilead’s Q2 2026 earnings show $7.8B revenue growth driven by HIV and NASH drugs, yet acquisition‑driven R&D charges turn the period into a net loss.

Dr. Michael Chen

06/08/2026, 08:42

4 minutes to read

Shionogi Expands Global Reach: Strategic Acquisitions & U.S. Manufacturing Boost

Shionogi expands globally, acquiring rare‑disease and infectious‑disease firms and boosting U.S. manufacturing to strengthen supply chains and diversify its drug portfolio.

Dr. Michael Chen

06/08/2026, 04:31

6 minutes to read

Novo Nordisk Boosts 2024 Outlook on Strong GLP‑1 Sales, Despite Pricing Headwinds

Novo Nordisk boosts 2024 outlook thanks to strong GLP‑1 sales, especially Wegovy, while navigating pricing pressures and expanding its oral semaglutide line.

Dr. Michael Chen

05/08/2026, 21:42

5 minutes to read

Older articles